Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03670069 · ClinicalTrials.gov registry record · Phase 1
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03670069 is a Phase 1 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 27 participants.
The verdict
NCT03670069, a Phase 1 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic). Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Itacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2024-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03670069
The ClinicalTrials.gov registry entry for NCT03670069 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03670069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03670069 about?
NCT03670069 is a clinical study titled "Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas". This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic). Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell ...
What is the current status of trial NCT03670069?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2019-09-30. Estimated completion is 2024-05-06.
What interventions are being tested in trial NCT03670069?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Itacitinib (DRUG).
Who is sponsoring clinical trial NCT03670069?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.